GlassScriptPhysician profile
Patrick B Hopen
NPI 1548585854
$8,289.31
in general payments reported to CMS, 2019-2025
26 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $363 · 2021: $2,469 · 2022: $857 · 2023: $1,353 · 2024: $1,952 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,528 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $498 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $498.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $1,927.43 | 2019-2021 | |
| Glaukos Corporation | $1,747.11 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Radius |
| Alcon Vision LLC | $1,262.82 | 2019-2025 | Hydrus Microstent, Wavelight Refractive Suite, Rocklatan |
| Allergan, INC. | $586.88 | 2019-2022 | |
| Abbvie INC. | $553.50 | 2022-2025 | |
| Rxsight INC | $415.62 | 2020-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $360.72 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $193.28 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Dompe US, INC. | $179.62 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $162.45 | 2021-2024 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $137.33 | 2024 | Syfovre |
| New World Medical,INC. | $128.01 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.63 | 2020-2021 | |
| Ivantis, INC | $98.69 | 2020-2021 | |
| Ocular Therapeutix, INC. | $88.65 | 2020-2024 | Dextenza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $63.04 | 2024-2025 | Iyuzeh |
| Biotissue Holdings INC. | $46.86 | 2019-2023 | |
| Harrow Eye, LLC | $43.51 | 2025 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $32.73 | 2022-2025 | Baerveldt Glaucoma Implant (250) |
| Mallinckrodt Hospital Products INC. | $30.58 | 2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $24.11 | 2025 | |
| Beaver-Visitec International, INC. | $21.32 | 2023 | |
| Shire North American Group INC | $20.45 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $20.37 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $18.01 | 2025 | Ryzumvi, Tyrvaya |
| Kala Pharmaceuticals, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hopen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.